PL352575A1 - Compositions of a-beta peptide and processes for producing same - Google Patents

Compositions of a-beta peptide and processes for producing same

Info

Publication number
PL352575A1
PL352575A1 PL00352575A PL35257500A PL352575A1 PL 352575 A1 PL352575 A1 PL 352575A1 PL 00352575 A PL00352575 A PL 00352575A PL 35257500 A PL35257500 A PL 35257500A PL 352575 A1 PL352575 A1 PL 352575A1
Authority
PL
Poland
Prior art keywords
compositions
processes
producing same
beta peptide
peptide
Prior art date
Application number
PL00352575A
Inventor
Pamela Hirtzer
Naina Patel
Original Assignee
Neuralab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab filed Critical Neuralab
Publication of PL352575A1 publication Critical patent/PL352575A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL00352575A 1999-06-01 2000-06-01 Compositions of a-beta peptide and processes for producing same PL352575A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13704799P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
PL352575A1 true PL352575A1 (en) 2003-08-25

Family

ID=22475602

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00352575A PL352575A1 (en) 1999-06-01 2000-06-01 Compositions of a-beta peptide and processes for producing same

Country Status (25)

Country Link
EP (1) EP1181040A1 (en)
JP (1) JP2003519620A (en)
KR (1) KR20020016813A (en)
CN (1) CN1353615A (en)
AR (1) AR024558A1 (en)
AU (1) AU5726100A (en)
BG (1) BG106249A (en)
BR (1) BR0011251A (en)
CA (1) CA2374897A1 (en)
CZ (1) CZ20014150A3 (en)
EE (1) EE200100649A (en)
HK (1) HK1045938A1 (en)
HR (1) HRP20010901A2 (en)
IL (1) IL146575A0 (en)
IS (1) IS6182A (en)
MX (1) MXPA01012355A (en)
NO (1) NO20015859L (en)
NZ (1) NZ515744A (en)
PE (1) PE20010212A1 (en)
PL (1) PL352575A1 (en)
RU (1) RU2001135800A (en)
SK (1) SK17012001A3 (en)
TR (1) TR200103476T2 (en)
WO (1) WO2000072870A1 (en)
ZA (1) ZA200109704B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US20040038302A1 (en) * 2000-09-19 2004-02-26 Roger Nitsch Methods and compounds for treating brain amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
ES2396555T3 (en) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Antibodies that recognize beta amyloid peptide
PE20061329A1 (en) 2004-12-15 2006-12-08 Neuralab Ltd HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
BRPI0619249A2 (en) 2005-11-30 2011-09-20 Abbott Lab anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
PT1976877E (en) 2005-11-30 2014-04-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
BRPI0709050B1 (en) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab antibody or fragment thereof, composition, methods for detecting ab protofibrils in vitro, and use of the antibody
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (en) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN105348387B (en) 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
HRP20210680T1 (en) 2014-07-10 2021-06-11 Bioarctic Ab Improved a-beta protofibril binding antibodies
AU2017205690B2 (en) 2016-01-08 2022-04-28 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
CN114957438B (en) * 2022-06-28 2024-04-02 福建亿彤生物科技有限公司 Human Aβ1-42 antigenic determinant polypeptide for detecting Alzheimer's disease and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2980677B2 (en) * 1990-04-27 1999-11-22 マクマイケル，ジョン Methods and compositions for the treatment of central nervous system disease states associated with abnormal amyloid beta protein
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
ZA200109704B (en) 2003-02-26
AR024558A1 (en) 2002-10-16
CA2374897A1 (en) 2000-12-07
JP2003519620A (en) 2003-06-24
SK17012001A3 (en) 2002-06-04
WO2000072870A1 (en) 2000-12-07
RU2001135800A (en) 2003-08-20
TR200103476T2 (en) 2002-04-22
IS6182A (en) 2001-11-29
NZ515744A (en) 2004-04-30
BG106249A (en) 2002-08-30
HRP20010901A2 (en) 2003-04-30
EE200100649A (en) 2003-02-17
IL146575A0 (en) 2002-07-25
EP1181040A1 (en) 2002-02-27
CZ20014150A3 (en) 2002-05-15
BR0011251A (en) 2002-03-05
AU5726100A (en) 2000-12-18
MXPA01012355A (en) 2003-06-24
HK1045938A1 (en) 2002-12-20
KR20020016813A (en) 2002-03-06
NO20015859L (en) 2002-02-01
PE20010212A1 (en) 2001-02-22
NO20015859D0 (en) 2001-11-30
CN1353615A (en) 2002-06-12

Similar Documents

Publication Publication Date Title
IL146575A0 (en) Compositions of a-beta peptide and processes for producing same
AU4133701A (en) Methods and compositions for peptide synthesis
AP2002002515A0 (en) Composition for ipregnation of fabrics and nettings
AU2002239262A1 (en) Compositions of peptide crystals
HUP0101580A3 (en) Pharmaceutical compositions capable of being gelled
IL140214A0 (en) Butterlike compositions and methods of manufacturing same
GB9924351D0 (en) Immunomodulation methods and compositions
BG105437A (en) Rheoogy modified compositions and processes thereof
EP1180006A4 (en) Compositions and methods for their preparation from lepidium
HUP0101243A3 (en) Novel compositions of eprosartan
HUP0202729A3 (en) Compositions for parenteral use of estramustine phosphate and amino acids
SG120874A1 (en) Process for the preparation of peptides
GB0126643D0 (en) Composition and process
HUP9904332A3 (en) Compositions and articles of manufacture
PL337804A1 (en) Solubilised compositions of sertralin
GB9926671D0 (en) Sealing of relatively movable parts
ZA200004376B (en) Process for the preparation of tetrapeptide
ZA988450B (en) Process for improving the plasticity of ceramic compositions and for reversing this effect
GB2338234B (en) Preparation of finasteride
EP1033999A4 (en) Compositions of leukaemia inhibitory factor
HUP0201410A3 (en) Compositions of a-betha peptide and processes for producing same
EP1100432A4 (en) Novel uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
EP1077892A4 (en) Process and composition for improving the uniformity of size application
IL121719A (en) Deicing composition and process of production thereof
IL154785A0 (en) Polymorphic form of finasteride and processes for the preparation thereof

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)